{
  "id": "mhgap#risk_safety_d0bacbd1",
  "content": "Cipriani A, Furukawa TA. A network meta-\n148. Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin\nanalysis of the effects of psychotherapies,\nFR, Fidalgo TM. Prescription psychostimulants\npharmacotherapies and their combination in the\nfor the treatment of stimulant use disorder:\ntreatment of adult depression. World Psychiatry.\na systematic review and meta-analysis.\n2020;19(1):92–107 (https://doi.org/10.1002/\nPsychopharmacology. 2020;237(8):2233–55\nwps.20701).\n(https://doi.org/10.1007/s00213-020-05563-3).\n141. Furukawa TA, Shinohara K, Sahker E, Karyotaki\n149. Nourredine M, Jurek L, Angerville B, Longuet Y, de\nE, Miguel C, Ciharova M et al. Initial treatment\nTernay J, Derveaux A et al. Use of topiramate in\nchoices to achieve sustained response in major\nthe spectrum of addictive and eating disorders:\ndepression: a systematic review and network\na systematic review comparing treatment\nmeta-analysis. World Psychiatry. 2021;20(3):387–\nschemes, efficacy, and safety features. CNS Drugs.\n96 (https://doi.org/10.1002/wps.20906).\n2021;35(2):177–213 (https://doi.org/10.1007/\n142. Chou R, Dana T, Blazina I, Grusing S, Fu R, s40263-020-00780-y).\nBougatsos C. Interventions for unhealthy drug\n150. Chan B, Freeman M, Ayers C, Korthuis PT,\nuse – supplemental report: a systematic review for\nPaynter R, Kondo K et al. A systematic review\nthe U.S. Preventive Services Task Force. Evidence\nand meta-analysis of medications for stimulant\nsynthesis No. 187. Rockville (MD): Agency for",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "work",
      "emotions",
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety Cipriani A, Furukawa TA. A network meta-\n148. Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin\nanalysis of the effects of psychotherapies,\nFR, Fidalgo TM. Prescription psychostimulants\npharmacotherapies and their combination in the\nfor the treatment of stimulant use disorder:\ntreatment of adult depression. World Psychiatry.\na systematic review and meta-analysis.\n2020;19(1):92–107 (https://doi.org/10.1002/\nPsychopharmacology. 2020;237(8):2233–55\nwps.20701).\n(https://doi.org/10.1007/s00213-020-05563-3).\n141. Furukawa TA, Shinohara K, Sahker E, Karyotaki\n149. Nourredine M, Jurek L, Angerville B, Longuet Y, de\nE, Miguel C, Ciharova M et al. Initial treatment\nTernay J, Derveaux A et al. Use of topiramate in\nchoices to achieve sustained response in major\nthe spectrum of addictive and eating disorders:\ndepression: a systematic review and network\na systematic review comparing treatment\nmeta-analysis. World Psychiatry. 2021;20(3):387–\nschemes, efficacy, and safety features. CNS Drugs.\n96 (https://doi.org/10.1002/wps.20906).\n2021;35(2):177–213 (https://doi.org/10.1007/\n142. Chou R, Dana T, Blazina I, Grusing S, Fu R, s40263-020-00780-y).\nBougatsos C. Interventions for unhealthy drug\n150. Chan B, Freeman M, Ayers C, Korthuis PT,\nuse – supplemental report: a systematic review for\nPaynter R, Kondo K et al. A systematic review\nthe U.S. Preventive Services Task Force. Evidence\nand meta-analysis of medications for stimulant\nsynthesis No. 187. Rockville (MD): Agency for Cipriani a, furukawa ta. a network meta-\n148."
}